August 2017 Issue of MMM
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
Executives discussed the challenges and opportunities they have faced as women.
Find out who made award-winning work this year.
Meet 13 of our 16 Hall of Femme honorees.
Our goal is to make gender parity a priority, and to keep our spotlight trained on it.
Read the August 2017 issue in its entirety, including our recap of the MM&M Hall of Femme event.
Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early ...
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to ...
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
As drugmakers hire economists and pharmacologists to better grapple with big data, how can ad agencies ensure they're not left behind?
"Other brands have missed the mark, with an apparent belief that once you hashtag it, they will come," she writes.
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.